Effects of GLP-1 RAs in weight reduction have been well documented, with several GLP-1 RAs (semaglutide and exenatide weekly injections) approved by FDA (Food and Drug Administration) for obesity management. The gene discussed is GLP1R; the disease is obesity disorder.